Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10990116 | 0.94 | ALDH1A1 (0.42) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5984583 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5986085 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5985234 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5986335 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5985177 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5985180 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5985606 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5984032 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 | |
| SCHEMBL5986326 | 0.90 | ALDH1A1 (0.36) | ALDH1A1TDP1TSHRCYP3A4CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3184553-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-05-01 | — | — | EP | disclosed |
| EP-2682409-B1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| EP-3184553-A1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-06-28 | — | — | EP | disclosed |
| US-9243077-B2 | Derivative of hyaluronic acid modified with amino-carboxylic acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-26 | — | — | US | disclosed |
| US-20130338352-A1 | DERIVATIVE OF HYALURONIC ACID MODIFIED WITH AMINO-CARBOXYLIC ACID | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-12-19 | — | — | US | disclosed |
| US-7018993-B2 | Antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20030158164-A1 | Novel antiandrogenic agent | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1304334-A1 | NOVEL ANTIANDROGENIC AGENT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-23 | — | — | EP | disclosed |
| EP-1219631-A1 | ANTIANDROGEN AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-07-03 | — | — | EP | disclosed |
| US-6410523-B1 | BONE DEFECTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-06-25 | — | — | US | disclosed |
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-04-18 | — | — | US | disclosed |
| US-20010021739-A1 | Latex compositions containing ethylenically unsaturated esters of fatty compounds and applications thereof | THE UNIVERSITY OF SOUTHERN MISSISSIPPI (US) | 2001-09-13 | — | — | US | disclosed |
| EP-1070704-A1 | VITAMIN D DERIVATIVES SUBSTITUTED AT THE 2$g(b)-POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-6174948-B1 | ADDITION POLYMERS WITH ESTER AND ETHER GROUPS | THE UNIVERSITY OF SOUTHERN MISSISSIPPI | 2001-01-16 | — | — | US | disclosed |
| EP-0632036-B1 | Amide derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO CO (JP) | 2000-03-01 | — | — | EP | disclosed |
| US-5614550-A | ANTICHOLESTEROL AGENTS OR ARTERIOSCLEROSIS AGENTS FOR HUMANS | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5534529-A | Substituted aromatic amides and ureas derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-09 | — | — | US | disclosed |
| EP-0632036-A2 | Amide and urea derivatives having anti-hypercholesteremic activity, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045772-A1 | Vitamin D derivative having substituent at 2beta-position | CYP2R1, CYP24A1, VDR | ALDH1A1 1662/4885TDP1 4663/4885TSHR 213/4885 |
| US-20030158164-A1 | Novel antiandrogenic agent | NR5A1, CYP19A1, HSD17B11 | ALDH1A1 399/4885TDP1 3394/4885TSHR 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.